Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

September 30, 2004

Conditions
Peritoneal CancerOvarian CancerNeoplasms, OvarianFallopian Tube Cancer
Interventions
DRUG

Topotecan

DRUG

Gemcitabine

Trial Locations (19)

14620

GSK Investigational Site, Rochester

20010

GSK Investigational Site, Washington D.C.

29601

GSK Investigational Site, Greenville

31902

GSK Investigational Site, Columbus

33021

GSK Investigational Site, Hollywood

37403

GSK Investigational Site, Chattanooga

39401

GSK Investigational Site, Hattiesburg

48075

GSK Investigational Site, Southfield

48912

GSK Investigational Site, Lansing

60521

GSK Investigational Site, Hinsdale

63117

GSK Investigational Site, Saint Louis

95032

GSK Investigational Site, Los Gatos

95403

GSK Investigational Site, Santa Rosa

27599-7570

GSK Investigational Site, Chapel Hill

19001-3788

GSK Investigational Site, Abington

T2N 4N2

GSK Investigational Site, Calgary

V5Z 4E6

GSK Investigational Site, Vancouver

K1H 1C4

GSK Investigational Site, Ottawa

M4N 3M5

GSK Investigational Site, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY